High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece

Background: Over the past few years there has been a remarkable increase in our knowledge of the variation in human genome. In parallel genotyping technologies have advanced significantly and allow sufficient throughput to accommodate genome-wide approaches. Hyperbilirubinemia is the most common adverse event in patients treated with atazanavir (ATV). Previous studies showed that polymorphisms in the uridine-glucuronosyl transferase (UGT1A1) enzyme and specifically the UGT1A1*28 variant may influence the risk of hyperbilirubinemia in patients treated with ATV/r. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P146 Cite this article as: Panagopoulos et al.: High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece. Journal of the International AIDS Society 2010 13(Suppl 4):P146. Full text: PubMed Central:  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112923/